Pfizer receives EC approval for Hympavzi to treat haemophilia
Pharmaceutical Business Review
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or The post Pfizer receives E
pharminent
May 14, 2026 (Last updated: May 14, 2026)
Pharmaceutical Business Review
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or The post Pfizer receives E